AUG 17, 2026 · PHASE 1/2 TRIAL
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
ClinicalTrials.gov
First-in-human Phase 1/2 open-label trial with planned enrollment of 201 participants; no results yet reported in this registry record.
Reported
Planned enrollment201
Primary outcome measure 1Treatment Emergent Adverse Events (TEAEs),…
Primary outcome measure 2Objective Response Rate (ORR), through dose…